Northland Securities reiterated their corporate rating on shares of SalvaRx Group Plc (LON:SALV) in a research note released on Tuesday.

Shares of SalvaRx Group Plc (LON:SALV) opened at 28.7495 on Tuesday. The company’s market capitalization is GBX 1.78 million. The company has a 50 day moving average price of GBX 27.90 and a 200 day moving average price of GBX 30.11. SalvaRx Group Plc has a 52 week low of GBX 22.25 and a 52 week high of GBX 37.00.

SalvaRx Group Plc Company Profile

SalvaRx Group PLC, formerly 3Legs Resources plc, is a United Kingdom-based drug discovery and development company. The Company focuses on immune-oncology. The Company focuses on cancer immuno-therapies, and provides its portfolio companies with operational support ranging from direct operation of subsidiaries to advisory or part-time involvement in various companies.

Receive News & Ratings for SalvaRx Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SalvaRx Group Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.